Biotech Values

[investorgold2002]

Jeffreis-halting of AIM-HIGH is +ve for AMR101

"Jefferies is out with its report today on Amarin (NASDAQ: AMRN), maintaining Buy.

In a note to clients, Jefferies writes, "The National Heart, Lung, and Blood Institute announced discontinuation of the AIM-HIGH trial, concluding that niacin with statin would not show benefit over statin alone in reducing cardiovascular-related complications. We continue to believe in a multi-billion market opportunity for AMR101, and AMRN remains one of our top biotech picks."

Jefferies maintains a $25 PT on AMRN.

Read more: http://www.benzinga.com/analyst-ratings/analyst-color/11/05/1117919/jefferies-maintains-buy-on-amarin#ixzz1NajA7egV
"